Eric Schmidt
Stock Analyst at Cantor Fitzgerald
(0)
# 4754
Out of 5,218 analysts
38
Total ratings
12.00%
Success rate
-21.22%
Average return
Main Sectors:
Top Industries:
| Name | Action | Price Target | Current | % Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
Tango Therapeutics | Reiterates: Overweight | n/a | n/a | n/a | 3 | Dec 5, 2024 | |
Incyte | Reiterates: Neutral | n/a | n/a | n/a | 5 | Nov 19, 2024 | |
Alumis | Reiterates: Overweight | n/a | n/a | n/a | 3 | Nov 14, 2024 | |
Bicara Therapeutics | Initiates Coverage On: Overweight | n/a | n/a | n/a | 1 | Oct 8, 2024 | |
Agios Pharmaceutical... | Reiterates: Overweight | n/a | n/a | n/a | 3 | Sep 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Reiterates: Overweight | 96 96 | 32.5 | 195.38% | 4 | Sep 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Reiterates: Neutral | n/a | n/a | n/a | 2 | Sep 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Reiterates: Overweight | n/a | n/a | n/a | 3 | Sep 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Reiterates: Overweight | n/a | n/a | n/a | 2 | Sep 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Reiterates: Overweight | 292 292 | 150.04 | 94.61% | 3 | Sep 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Reiterates: Neutral | n/a | n/a | n/a | 3 | Aug 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Overweight | n/a | n/a | n/a | 1 | May 30, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Reiterates: Overweight | 370 | 463.5 | -20.17% | 1 | Oct 17, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Downgrades: Neutral | n/a | n/a | n/a | 1 | Oct 17, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Upgrades: Outperform | n/a | n/a | n/a | 1 | Jul 10, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Outperform | 31 | n/a | n/a | 1 | Jun 12, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Outperform | n/a | n/a | n/a | 1 | May 30, 2017 |